Clinical trial NCT00460616 - References

Prolactinomas — Cardiac Valve Complications in Prolactinomas Treated With Cabergoline

Citation(s)

•   Botero M, Fuchs R, Paulus DA, Lind DS
  Carcinoid heart disease: a case report and literature review. J Clin Anesth. 2002 Feb;14(1):57-63. Review.
•   Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee
  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):2560-72. Epub 2003 May 14. Erratum in: JAMA. 2003 Jul 9;290(2):197.
•   Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G
  Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med. 2003 Nov 20;349(21):2023-33.
•   Flowers CM, Racoosin JA, Lu SL, Beitz JG
  The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc. 2003 Jun;78(6):730-1.
•   Gillam MP, Molitch ME, Lombardi G, Colao A
  Advances in the treatment of prolactinomas. Endocr Rev. 2006 Aug;27(5):485-534. Epub 2006 May 26. Review.
•   Nutt JG, Wooten GF
  Clinical practice. Diagnosis and initial management of Parkinson's disease. N Engl J Med. 2005 Sep 8;353(10):1021-7. Review.
•   Pinero A, Marcos-Alberca P, Fortes J
  Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med. 2005 Nov 3;353(18):1976-7.
•   Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E
  Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007 Jan 4;356(1):29-38.
•   Serratrice J, Disdier P, Habib G, Viallet F, Weiller PJ
  Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev. 2002 Nov-Dec;10(6):334-6.
•   Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C, Schoors D
  Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet. 2004 Apr 10;36
•   Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G
  Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007 Jan 4;356(1):39-46.

Observational Study to Investigate the Prevalence of Cardiac Abnormalities and Valvular Regurgitation in Patients With Prolactinomas Treated Chronically With Cabergoline

Details for clinical trial NCT00460616